http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PH-12019501249-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c564804e4e89ea0871bbeefd81569950
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24
filingDate 2019-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6efa15087708bd83bf112dd4e6f3349
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6b2c819774747669b321e54320bf1b2
publicationDate 2019-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PH-12019501249-A1
titleOfInvention Pharmaceutical preparation and method for its manufacture
abstract A solid pharmaceutical preparation The present invention refers to a pharmaceutical preparation (10) comprising a first pharmaceutical composition having a matrix material and pharmaceutically active ingredients distributed within the matrix material, wherein the first pharmaceutical composition comprises Praziquantel, Pyrantel and Febantel as pharmaceutical active ingredients, wherein the preparation (10) comprises a second pharmaceutical composition having a matrix material and at least one of avermectins and milbemycins such as Moxidectin as pharmaceutically active ingredient distributed within the matrix material, wherein the preparation (10) is provided in a multi-layer structure such, that the first composition is provided in a first layer (12) and the second composition is provided in a second layer (14), wherein the first layer (12) and the second layer (14) are separated by a barrier layer (16) being provided between the first layer (12) and the second layer (14).
priorityDate 2016-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16760141
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414375346
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID708857
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4891
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135449328
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420466226
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534699
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426149772

Total number of triples: 33.